Merck
CN
  • Link between obesity and cancer: role of triglyceride/free fatty acid cycling.

Link between obesity and cancer: role of triglyceride/free fatty acid cycling.

European review for medical and pharmacological sciences (2014-10-24)
Y Gong, L-J Dou, J Liang
摘要

Obesity has long been suspected to be a risk factor for cancer. The relationship between body fat deposition and the pathogenesis of cancer has been the subject of many studies, however, no clear consensus has emerged linking these two biological processes. Recent epidemiological studies showed a strong association between cancer-related deaths and increased body-mass index. In fact, obesity has been identified as a cause for oesophageal, colon, uterine, kidney and post-menopausal breast cancers and also as a significant risk factor for the cancers of prostate, pancreas and non-Hodgkin lymphoma. Approximately 16-20% of cancer deaths in women and 14% of cancer deaths in men were found to be due to obesity. It is also recognized that there is a positive relationship between type-2 diabetes associated hyperinsulinemia and cancer incidence. Though the recent annual report in US finds that the incidence and mortality rates for many cancers have dropped in 2003 since 1975, this decline is mostly due to a substantial decrease in tobacco use among men. However, during the same period the rise in the prevalence of obesity might have contributed to the increased risk and incidence of prostate, liver, kidney, oesophageal and breast cancers. Whether the elevated cancer risk in obesity arises from similar modulation of parallel signaling/metabolic pathways during adipogenesis and oncogenesis has not been hitherto addressed. In this Review we would like to bring out the similarities between adipogenesis and oncogenesis and how this relationship at molecular level may be relevant for the development of effective therapeutics for obesity, diabetes and cancer. While adipogenesis is the process of formation of mature adipocytes or fat cells under normal physiological conditions, oncogenesis is a pathological process, which results in the uncontrolled growth of cells leading to cancer. Though, both these processes at surface seem to be totally different, we believe that there are important common denominators for these processes that need to be recognized. We will discuss the role of two such underlying factors - (1) malonyl-CoA, an important regulator of fatty acid metabolism and (2) triglyceride/free fatty acid (TG/FFA) cycling which is central to the generation of multiple signals for controlling various metabolic, physiological and signaling pathways in the cell.

材料
货号
品牌
产品描述

Sigma-Aldrich
β-烟酰胺腺嘌呤二核苷酸 水合物, ≥96.5% (HPLC), ≥96.5% (spectrophotometric assay), from yeast
Sigma-Aldrich
烟酰胺, BioReagent, suitable for cell culture, suitable for insect cell culture
Supelco
烟酰胺, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
β-烟酰胺腺嘌呤二核苷酸 水合物, ≥99%
Sigma-Aldrich
烟酰胺, ≥99.5% (HPLC)
Sigma-Aldrich
烟酰胺, ≥98% (HPLC), powder
Sigma-Aldrich
β-烟酰胺腺嘌呤二核苷酸 水合物, Grade AA-1
Sigma-Aldrich
烟酰胺, meets USP testing specifications
Sigma-Aldrich
β-烟酰胺腺嘌呤二核苷酸 水合物, ≥95% (HPLC)
Sigma-Aldrich
β-烟酰胺腺嘌呤二核苷酸 水合物, ≥98%, BioUltra, from yeast
Sigma-Aldrich
β-烟酰胺腺嘌呤二核苷酸, pkg of 10 mg (per vial)
Sigma-Aldrich
β-烟酰胺腺嘌呤二核苷酸 水合物, purified by column chromatography, ≥99%
Sigma-Aldrich
β-烟酰胺腺嘌呤二核苷酸, pkg of 50 mg (per vial)
USP
烟酰胺, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
β-烟酰胺腺嘌呤二核苷酸 水合物, suitable for cell culture, ≥96.5% (HPLC), ≥96.5% (spectrophotometric assay), from yeast
Sigma-Aldrich
β-烟酰胺腺嘌呤二核苷酸, pkg of 20 mg (per vial)
Sigma-Aldrich
烟酰胺, ≥98.5% (HPLC)
Sigma-Aldrich
β-烟酰胺腺嘌呤二核苷酸 锂盐 来源于酿酒酵母, ≥95%
烟酰胺, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
β-烟酰胺腺嘌呤二核苷酸 水合物, Vetec, reagent grade, ≥96.5%